FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
Together, the ILLUMINATE studies comprise a comprehensive clinical development program intended to demonstrate the safety and efficacy of Oxlumo across the full spectrum of patients diagnosed with PH1. 0.514 mmol/24 hr/1.73 0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 IMPORTANT SAFETY INFORMATION.
52 
Let's personalize your content